IBL-302

IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma. IBL-302 demonstrated in vivo efficacy in a nude mouse xenograft model, inhibiting trastuzumab (HY-P9907) resistance challenges. IBL-302 also enhances the effects of common cytotoxic chemotherapy drugs cisplatin (HY-17394), doxorubicin (HY-15142A), and etoposide (HY-13629) [1][2][3].

Product Specifications

CAS Number

[1414455-21-2]

Product Name Alternative

AMU302

UNSPSC

12352005

Target

Akt; mTOR; PI3K; Pim

Type

Reference compound

Related Pathways

JAK/STAT Signaling; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ibl-302.html

Purity

98.21

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1=C(C(C=C2N[S](=O)(C(C=C3)=C4)=O)=CN=C2OC)SC5=C1N=CN=C5C6=CC=C(CNC(C4=C3F)=O)S6

Molecular Formula

C25H18FN5O4S3

Molecular Weight

567.63

References & Citations

[1]Kennedy SP et al. Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer. Oncogene. 2020 Apr;39 (14) :3028-3040.|[2]Martínez-González S, et al. Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors. ACS Med Chem Lett. 2021 Nov 2;12 (11) :1794-1801.|[3]Kennedy S P, et al. Evaluation of dual-acting PIM/PI3K inhibitor IBL-302 in preclinical breast cancer models[J]. Cancer Research, 2018, 78 (13_Supplement) : 2932-2932.